SARS-COV-2 IgG antibody response in pregnant women at delivery

Vassilis Tsatsaris; Alice-Andrée Mariaggi; Odile Launay; Camille Couffignal; Jessica Rousseau; Pierre Yves Ancel; Estelle Marcault; Yves Ville; Anne-Gaël Cordier; Alexandre Vivanti; Julie Carrara; Dominique Luton; Marc Dommergues; Constance Borie; Gilles Kayem; Vivien Alessandrini; Laurence Lecomte; Jean François Meritet; Marianne Leruez-Ville; François Goffinet; Claire Dubois; Olivier Picone; Christelle Vauloup Fellous

doi:10.1016/j.jogoh.2020.102041

SARS-COV-2 IgG antibody response in pregnant women at delivery

J Gynecol Obstet Hum Reprod. 2021 Sep;50(7):102041. doi: 10.1016/j.jogoh.2020.102041. Epub 2020 Dec 10.

Authors

Vassilis Tsatsaris¹, Alice-Andrée Mariaggi², Odile Launay³, Camille Couffignal⁴, Jessica Rousseau⁵, Pierre Yves Ancel⁶, Estelle Marcault⁴, Yves Ville⁷, Anne-Gaël Cordier⁸, Alexandre Vivanti⁹, Julie Carrara¹⁰, Dominique Luton¹¹, Marc Dommergues¹², Constance Borie¹³, Gilles Kayem¹⁴, Vivien Alessandrini¹⁵, Laurence Lecomte⁵, Jean François Meritet¹⁶, Marianne Leruez-Ville¹⁷, François Goffinet¹⁵, Claire Dubois¹⁸, Olivier Picone¹⁹, Christelle Vauloup Fellous²⁰

Affiliations

¹ Université de Paris, F-75006 Paris, France; Maternité Port-Royal, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France. Electronic address: [email protected].
² Université de Paris, F-75006 Paris, France; Laboratoire de Virologie, AP-HP, Hôpital Cochin, F-75014 Paris, France.
³ Université de Paris, F-75006 Paris, France; CIC vaccinologie, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France.
⁴ Université de Paris, F-75006 Paris, France; Unité de recherche clinique PNVS, AP-HP, Hôpital Bichat, F-75018 Paris, France.
⁵ Unité de recherche clinique, CIC-Mère enfant, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France.
⁶ Université de Paris, F-75006 Paris, France; Unité de recherche clinique, CIC-Mère enfant, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France.
⁷ Université de Paris, F-75006 Paris, France; Maternité, AP-HP, Hôpital Necker, F-75007 Paris, France.
⁸ Maternité, AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France.
⁹ Université Paris-Saclay, 94804 Villejuif, France; Maternité, AP-HP, Hôpital Antoine Béclère, F-92140 Clamart, France.
¹⁰ Maternité, AP-HP, Hôpital Antoine Béclère, F-92140 Clamart, France.
¹¹ Université de Paris, F-75006 Paris, France; Maternité, AP-HP, Hôpital Bichat, F-75018 Paris, France; Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France.
¹² Sorbonne Université, F-75006 Paris, France; Maternité, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.
¹³ Université de Paris, F-75006 Paris, France; Maternité, AP-HP, Hôpital Robert Debré, F-75019 Paris, France.
¹⁴ Sorbonne Université, F-75006 Paris, France; Maternité, AP-HP, Hôpital Trousseau, F-75012 Paris, France.
¹⁵ Université de Paris, F-75006 Paris, France; Maternité Port-Royal, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France.
¹⁶ Maternité Port-Royal, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France.
¹⁷ Laboratoire de Virologie, AP-HP, Hôpital Necker, F-75007 Paris, France.
¹⁸ Université de Paris, F-75006 Paris, France; Laboratoire de Virologie, AP-HP, Hôpital Paul-Brousse, F-94804 Villejuif, France.
¹⁹ Université de Paris, F-75006 Paris, France; Maternité, AP-HP, Hôpital Louis Mourier, F-75007 Paris, France.
²⁰ Université Paris-Saclay, 94804 Villejuif, France; Laboratoire de Virologie, AP-HP, Hôpital Paul-Brousse, F-94804 Villejuif, France.

Abstract

Background: The prevalence of COVID-19 infection during pregnancy is not known. COVIPREG is a prospective French multicenter study to assess the seroprevalence at the time of delivery and the maternal and neonatal impact of COVID-19 infection during pregnancy. In order to study factors associated with poor outcomes after COVID-19 Infection during pregnancy and adapt the sample size of the study, a preliminary assessment of the prevalence of SARS-CoV-2 IgG was planned after 500 inclusions in a one perinatal center of Paris area.

Objectives: To assess the prevalence of SARS-CoV-2 IgG antibody response in pregnant women at the time of delivery during the COVID-19 pandemia.

Study design: A prospective observational study at Cochin hospital (Level III maternity). Patients admitted for delivery were offered to participate to the study. Each patient participating to the study was tested for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA.

Results: Among the 529 patients included in the COVIPREG study between April 29 and June 26, 529 were assessed for SARS-CoV-2 IgG antibody response and 25 had a positive test, ie 4.7 % with a confidence interval at 95 % [3.0 %-6.9 %]).

Conclusions: Four months after the beginning of the infection in Paris, the seroprevalence of SARS-CoV-2 IgG in pregnant women at the time of delivery is low. Studies evaluating the impact of COVID-19 infection during pregnancy should take this information in account in order to adapt the sample size.

Keywords: COVID-19; Pregnancy; SARS-CoV-2; Seroprevalence.

Publication types

Multicenter Study
Observational Study

MeSH terms

Adult
Antibodies, Viral / blood*
Antibody Formation / immunology
COVID-19 / epidemiology
COVID-19 / immunology*
COVID-19 / virology
Female
France / epidemiology
Gestational Age
Humans
Immunoglobulin G / blood*
Infant, Newborn
Paris / epidemiology
Parturition
Pregnancy
Pregnancy Complications, Infectious / epidemiology
Pregnancy Complications, Infectious / virology*
Pregnancy Outcome
Prospective Studies
SARS-CoV-2 / immunology*
Seroepidemiologic Studies

Substances

Antibodies, Viral
Immunoglobulin G